Ablynx (Euronext Brussels: ABLX) is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, haematology, oncology and pulmonary disease.
The Company is headquartered in Ghent, Belgium.
65 Gresham Street,
London, EC2V 7NQ
T: +44 (0)20 7457 2020
© 2017 Instinctif Partners – Registered in England & Wales No 1036926 / VAT No 245666930 | visit our global website instinctif.com